EDDING GENOR GROUP HOLDINGS LIMITED
亿腾嘉和醫藥集團有限公司
(formerly known as Genor Biopharma Holdings Limited
嘉和生物藥業(開曼)控股有限公司)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE

This announcement is made on a voluntary basis by Edding Genor Group Holdings Limited (the "**Company**").

Pursuant to the general and unconditional mandate (the "**Repurchase Mandate**") granted to the board (the "**Board**") of directors (the "**Directors**") of the Company by the shareholders of the Company at the annual general meeting held on 26 June 2026 (the "**2026 AGM**"), the Directors are authorized to repurchase up to 10% of the total number of issued shares of the Company in issue (excluding any treasury shares of the Company) on the date of the 2026 AGM (the "**Repurchase Cap**").

The Board is pleased to announce that the Board resolved to exercise its authority under the Repurchase Mandate to repurchase shares of the Company (the "**Shares**") up to the Repurchase Cap from the open market subject to market conditions, and the repurchase price of each Share shall be no more than 5% higher than the average closing market price for the Shares over the five trading days immediately preceding each repurchase (the "**Proposed Share Repurchase**"). The Proposed Share Repurchase shall be completed prior to the date of the 2027 annual general meeting of the Company and Shares repurchased by the Company will be used for employee incentives, market capitalization management or other purposes deemed by the Company to be beneficial to the Company's operation. The Board believes that the Proposed Share Repurchase is in the best interests of the Company and its shareholders as a whole.

Shareholders and potential investors should note that any repurchase to be made by the Company will be subject to market conditions and compliance with applicable laws and regulations, any regulatory requirements in connection with the repurchase as well as the provisions of the articles of association of the Company. The Company makes no assurance as to the timing, quantity or price of any repurchase of Shares. Accordingly, shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 7 July 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.